Explore 3 Stock Ideas & Industry Insights Download Free Report

AgeX Therapeutics Inc

Company price
None USD 0.00(0%)
Last update at 2024-04-29T17:27:10.958781Z
Market Cap
14.90M

Momentum Score

…

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.33
Low
1.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.09M
Revenue Per Share
0.00
Gross Profit TTM
0.12M
Debt / Equity
-1.05
ROE
-
Net Debt
17.48M
ROCE
102.02%
Diluted EPS TTM
-0.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -10.52M -8.58M -11.13M -12.24M -7.73M
Minority interest 0.06M 0.01M -0.28M 0.40M 0.78M
Net income -10.67M -10.22M -10.98M -12.38M -7.50M
Selling general administrative 5.97M 6.71M 7.40M 8.14M 5.65M
Gross profit 0.02M 0.12M 1.71M 1.48M 1.03M
Reconciled depreciation 0.13M 0.13M 1.68M 0.95M 0.54M
Ebit -6.97M -8.04M -10.67M -12.56M -11.24M
Ebitda -6.83M -7.46M -8.99M -11.61M -10.71M
Depreciation and amortization 0.14M 0.58M 1.68M 0.95M 0.54M
Non operating income net other - - 0.04M 0.29M 3.40M
Operating income -6.97M -8.04M -10.67M -12.56M -11.24M
Other operating expenses 7.01M 8.18M 12.54M 14.29M 12.64M
Interest expense 3.33M 1.10M 0.50M 0.55M 0.12M
Tax provision - 0.00M -0.15M 0.15M -
Interest income 3.33M 1.10M 0.50M 0.03M 3.33M
Net interest income -3.33M -1.10M -0.50M 0.03M 0.12M
Extraordinary items 0.00M -0.10M -0.62M - 0.00M
Non recurring - - - - 0.80M
Other items - - - - 0.00M
Income tax expense 0.15M 1.64M -0.15M 0.15M 3.51M
Total revenue 0.03M 0.14M 1.87M 1.73M 1.40M
Total operating expenses 7.00M 8.16M 12.38M 14.04M 12.28M
Cost of revenue 0.01M 0.02M 0.16M 0.24M 0.36M
Total other income expense net -3.55M -0.54M -0.46M 0.32M 3.40M
Discontinued operations - -0.10M -0.47M -0.47M -0.47M
Net income from continuing ops -10.52M -8.58M -10.98M -12.38M -7.73M
Net income applicable to common shares -10.46M -8.68M -10.87M -12.15M -7.50M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 3.24M 3.15M 3.92M 7.44M 10.67M
Intangible assets 0.74M 0.87M 1.59M 2.15M 2.71M
Other current assets 1.80M 1.62M 1.43M 1.34M 1.01M
Total liab 20.56M 15.03M 9.32M 4.83M 2.44M
Total stockholder equity -17.21M -11.83M -5.12M 2.22M 7.45M
Deferred long term liab - - - - 0.00M
Other current liab 1.40M 0.99M 1.26M 1.27M 0.62M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -116.21M -105.75M -97.07M -86.21M -74.05M
Other liab - - 0.06M - 0.00M
Good will - - - - 0.00M
Other assets 0.05M 0.05M 0.05M 0.11M 0.02M
Cash 0.65M 0.58M 0.53M 2.35M 6.71M
Cash and equivalents 0.65M 0.58M 0.53M 2.35M 6.71M
Total current liabilities 10.08M 8.97M 5.36M 3.30M 2.44M
Current deferred revenue - 0.07M 0.28M 0.28M 0.32M
Net debt 17.48M 12.62M 5.77M -0.40M -6.71M
Short term debt 7.65M 7.14M 2.40M 0.43M 0.08M
Short long term debt 7.65M 7.14M 2.40M - 0.00M
Short long term debt total 18.12M 13.20M 6.30M 1.96M -
Other stockholder equity 98.99M 93.91M 91.81M 88.35M 81.50M
Property plant equipment - - 0.00M 1.13M 0.09M
Total current assets 2.45M 2.23M 2.28M 4.05M 7.85M
Long term investments - - - - 0.00M
Net tangible assets - -12.70M -6.71M 0.07M 4.74M
Short term investments - - - - 0.00M
Net receivables 0.00M 0.03M 0.33M 0.36M 0.13M
Long term debt 10.48M 6.06M 3.90M 1.53M 0.00M
Inventory - - - - 0.00M
Accounts payable 1.03M 0.77M 1.43M 1.32M 1.42M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - -0.28M 0.40M 0.78M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income - - 0.14M 0.07M -0.00M
Additional paid in capital - - - - 0.00M
Common stock total equity - - 0.00M 0.00M 0.00M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - -97.07M -86.21M -74.05M
Treasury stock - - - - 0.00M
Accumulated amortization - - - - 0.00M
Non currrent assets other 0.05M 0.05M 0.05M 0.11M 0.02M
Deferred long term asset charges - - - - 0.00M
Non current assets total 0.79M 0.92M 1.64M 3.39M 2.82M
Capital lease obligations - - 0.00M 0.43M 0.00M
Long term debt total 10.48M 6.06M 3.90M 1.53M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00M 0.67M -0.02M 0.35M 3.21M
Change to liabilities - -0.77M 0.40M -0.62M 0.39M
Total cashflows from investing activities 0.00M 0.67M -0.02M -0.36M 1.33M
Net borrowings - 7.00M 6.12M 1.76M 1.76M
Total cash from financing activities 6.00M 7.25M 5.96M 6.26M 6.00M
Change to operating activities - -0.24M -0.47M -0.31M -0.55M
Net income -10.52M -8.58M -10.98M -12.38M -7.73M
Change in cash 0.06M 0.06M -1.88M -4.25M -0.67M
Begin period cash flow 0.63M 0.58M 2.45M 6.71M 7.38M
End period cash flow 0.69M 0.63M 0.58M 2.45M 6.71M
Total cash from operating activities -5.94M -7.86M -7.82M -10.16M -8.00M
Issuance of capital stock 0.00M 0.50M - 0.00M 5.00M
Depreciation 0.13M 0.13M 1.68M 0.95M 0.54M
Other cashflows from investing activities 0.00M 0.67M 0.20M -0.07M -1.87M
Dividends paid - - - - 0.00M
Change to inventory - -0.13M -0.01M 0.23M -0.42M
Change to account receivables 0.02M 0.13M 0.01M -0.23M -0.02M
Sale purchase of stock 0.00M 0.50M - 4.50M 0.24M
Other cashflows from financing activities 5.99M 6.75M 5.96M 6.24M 0.76M
Change to netincome - 0.46M 0.94M 1.78M -0.72M
Capital expenditures 0.00M 0.00M 0.02M 0.64M 1.89M
Change receivables - - 0.01M -0.23M -0.02M
Cash flows other operating - - 1.01M 0.52M -0.22M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - -1.88M -4.26M -0.67M
Change in working capital 0.33M -0.88M -0.06M -0.41M 0.21M
Stock based compensation 0.76M 1.00M 0.93M 1.91M 1.47M
Other non cash items 3.36M 1.11M 0.49M 0.05M 0.80M
Free cash flow -5.94M -7.86M -7.84M -10.80M -9.89M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

AgeX Therapeutics Inc

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

1101 Marina Village Parkway, Alameda, CA, United States, 94501

510 671 8370

5

Name Title Year Born
Dr. Michael D. West Ph.D. Founder, Pres, CEO & Director 1953
Ms. Eun-Jae Park CPA Chief Financial Officer 1972
Dr. Nafees Naseer Malik M.D. Chief Operating Officer 1978
Dr. Ivan Labat Chief Information Officer NA
Ms. Judith Segall Sec. 1953

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…